Updates & Evolving Care Considerations in the Mitigation of Hyperkalemia in Patients with End-Stage Renal Disease on Dialysis




Though rare in the general population, hyperkalemia often occurs among patients with CKD, particularly among older individuals in advanced stages of the disease. Patients with hyperkalemia are predisposed to cardiac hyperexcitability & depression, both of which can be fatal, particularly if not treated rapidly. This educational activity will provide a review of hyperkalemia, including a discussion of the associated health burden, risk factors, & evidence-based management strategies. In addition, recent FDA approvals & clinical trial data supporting improved outcomes in high-risk patients will also be considered.


George L. Bakris, MD
Professor of Medicine
Director, AHA Comprehensive HTN Center
University of Chicago Medicine
Chicago, Illinois


Biff F. Palmer, MD
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, Texas


Release date: July 22, 2021
Expiration date: July 22, 2022
Estimated time to complete activity: 30 minutes



This educational activity has been designed to meet the needs of US-based healthcare professionals, including nephrology physician assistants, nurse practitioners and patients.


Upon completion of this educational activity, participants should be able to:

  • Describe the associated morbidity & mortality burdens & factors & exposures that increase the risk of hyperkalemia in patients with ESRD
  • Integrate current evidence-based standards of care & prescribing information to individualize treatment for hyperkalemia in patients with ESRD on HD
  • Review recent clinical trial outcomes expanding on the use of treatments for hyperkalemia, particularly among patients with ESRD on HD

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2021 through July 22, 2022, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.




Physician Continuing Education


Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Integrity Continuing Education designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.


Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

George L. Bakris, MD
Consulting Fees: Merck, Ionis, Astra-Zeneca, Bayer, Novo Nordisk, Vascular Dynamics
Steering Committee Clinical Trials: Vascular Dynamics, Novo Nordisk, Bayer

Biff F. Palmer, MD has nothing to disclose.

The Integrity Continuing Education planners and managers have nothing to disclose.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)


Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.


Provided by Integrity Continuing Education.


Supported by an educational grant from AstraZeneca Pharmaceuticals LP.


Continue to Pretest